The surgical treatment of medullary thyroid carcinoma

Seminars in Surgical Oncology

Volumn 16, Issue 1, 1999, Pages 50-63

  Evans, Douglas B ^a   Fleming, Jason B ^a   Lee Jeffrey, E ^a   Cote, Gilbert ^a   Gagel, Robert F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adjuvant radiotherapy; Calcitonin; Carcinocmbryonic antigen; Medullary carcinoma; Multiple endocrine ncoplasia; Mutation; Neoplasm staging; Pentagastrin; Phcochromocytoma; Postoperative complications; Proto oncogenes; Reoperation; Thyroid neoplasms; Thyroidectomy

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; PENTAGASTRIN;

CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; FAMILIAL CANCER; FOLLOW UP; HIRSCHSPRUNG DISEASE; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; PHEOCHROMOCYTOMA; POINT MUTATION; PRIORITY JOURNAL; PROTO ONCOGENE; RADIATION DOSE; REOPERATION; REVIEW; SURGICAL TECHNIQUE; THYROID CARCINOMA; THYROIDECTOMY;

CALCITONIN; CARCINOMA, MEDULLARY; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; NECK DISSECTION; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0031782893     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2388(199901/02)16:1<50::aid-ssu9>3.0.co;2-6     Document Type: Article

References (41)

1. Easton DF, Ponder MA, CummingsT, et al: The clinical and screening ae-at-onset distribution for the MEN-2 syndrome. Am J Hum GeneT 1989;44:208-215.
2. Gagel RF, Levy ML, Donovan DT, et al: Multiple endocrine neoplasia type 2A associated with cutaneous lichen amyloidosis [comment in Ann Intern Med 1990;! 12:551-552]. Ann Intern Med 1989;111:802-806.
3. Verdy M, Weber AM, Roy CC, et al: Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1982;1:603-607.
4. Girelli ME, Nacamulli D, Pelizzo MR, et al: Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986. Thyroid 1998;8:517-523.
5. Wohll N, Cote GJ, Evans DB, et al: Application of genetic screen-ing information lo the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2 [Review]. Endocrinol Metab Clin North Am 1996;25:l-25.
6. Eng C: Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease [Review]. N Engl J Med 1996;335:943-951.
7. Landsvater RM, de Wit MJ, Zewald RA, et al: Somatic mutations of the RET proto-oncogene are not required for tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers. Cancer Res 1996;56:4853-4855.
8. Eng C, Clayton D, Schuffenecker I, et al: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA I996;276:1575-1579.
9. Marsh DJ, Learoyd DL, Andrew SD, et al: Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 1996:44:249-257.
10. Dottorini ME, Assi A, Sironi M, et al: Multivariate analysis of patients with medullary thyroid carcinoma. Cancer 1996;77:1556-1565.
11. Fuchshuber PR, Loree TR, Hicks VVL Jr, et al: Medullary carcinoma of the thyroid: prognostic factors and treatment recommendations. Ann Surg Oncol 1998;5:81-86.
12. Kallinowski F, Buhr HJ, Meybier H, et al: Medullary carcinoma of the thyroid-therapeutic strategy derived from fifteen years of experience. Surgery 1993;! 14:491-496.
13. Schröder S, Bocker W, Baisch H, et al: Prognostic factors in medullary thyroid carcinomas. Cancer 1988;61:806-816.
14. Evans DB, Burgess MA, Goepfert H, Gagel RF: Medullary thyroid cancer. In Bardin CW (ed): "Current therapy in endocrinology and metabolism." 6lh ed. St. Louis, MO: Mosby-Year Book; 1997. p. 127-132.
15. Tisell LE, Dilley WG, Wells SA Jr: Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery 1996; 119:34-39.
16. Buhr HJ, Kallinowski F, Raue F, et al: Microsurgical neck dissection for metastasizing medullary thyroid carcinoma. Eur J Surg Oncol 1995;21:195-197.
17. Gimm O, Dralle H: Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery 1997:122:1124-1131.
18. Moley JF, Wells SA, Dilley WG, Tisell LE: Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993; 114:10901096.
19. van Heerden JA, Grant CS, Gharib H, et al: Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990;212:395-401.
20. Brierley J, Tsang R, Simpson WJ, et al: Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996:6:305-310.
21. Saad MF, Ordonez NG, Rashid RK, et al: Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 1984;63:319-342.
22. Samaan NA, Schultz PN, Hickey RC: Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988:67:801-805.
23. Simpson WJ, Palmer JA, Rosen IB, Mustard RA: Management of medullary carcinoma of the thyroid. Am J Surg 1982;I44:420-422.
24. Gharib H, McConahey \VM, Tiegs RD, et al: Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clinic Proceedings 1992;67:934-940.
25. Dralle H, Damm I, Scheumann GF, et al: Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994;24:112-121.
26. Marzano LA, Porcelli A, Biondi B, et al: Surgical management and follow-up of medullary thyroid carcinoma. J Surg Oncol 1995;59:162-168.
27. Miller HH, Melvin KE, Gibson JM, Tashjian AH Jr: Surgical approach to early familial medullary carcinoma of the thyroid gland. Am J Surg 1972;123:438-443.
28. Gimm O, Ukkat J, Dralle H: Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma.World J Surg 1998;22:562-568.
29. Udelsman R, Lakatos E, Ladenson P: Optimal surgery for papillary thyroid carcinoma [Review]. World J Surg 1996;20:88-93.
30. Abdelmoumene N, Schlumberger M, Gardet P, et al: Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer 1994;69:1141-1144.
31. Frank-Raue K, Raue F, Buhr HJ, et al: Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid 1992;2:113-117.
32. Ben Mrad MD, Gardet P, Roche A, et al: Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma. Cancer 1989;63:133-138.
33. Gautvik KM, Talle K, Hager B, et al: Early liver métastases in patients with medullary carcinoma of the thyroid gland. Cancer 1989;63:175-180.
34. Norton JA, Doppman JL, Brennan MF: Localization and resection of clinically inapparent medullary carcinoma of the thyroid. Surgery 1980;87:616-622.
35. Tung WS, Vesely TM, Moley JF: Laparoscopic detection of hepatic métastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995; 118:1024-1030.
36. Baudin E, Lumbroso J, Schlumberger M, et al: Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912-916.
37. Behr TM, Gratz S, Markus PM, et al: Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 1997;80:2436-2457.
38. Tisell LE, Ahlman H, Wangberg B, et al: Somatostatin receptor scintigraphy in medullary thyroid carcinoma. Br J Surg 1997; 84:543-547.
39. Waddington WA, Kettle AG, Heddle RM, Coakley AJ: Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med 1994;21:363-364.
40. Norton JA, Doppman JL, Brennan MF: Localization and resection of clinically inapparent medullary carcinoma of the thyroid. Surgery 1980;87:616-622.
41. Tisell LE, Hansson G, Jansson S, Salander H: Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986;99:60-66.